In the present study, a new prognostic scale for risk stratification of AML patients based on the drug responsiveness of tumor cells detected in vitro as well as MDR1 mRNA/P-glycoprotein expression, tumor origin (primary or secondary), cytogenetic abnormalities, and aberrant immunophenotype was developed. The gene discussed is ABCB1; the disease is neoplasm.